Literature DB >> 7618812

Transanal excision of rectal carcinoma.

R C Frazee1, R Patel, M Belew, J W Roberts, J C Hendricks.   

Abstract

Twenty-two men and 16 women with a mean age of 67 years were treated for rectal carcinoma by transanal excision. Patients presented with rectal bleeding (63%), change in bowel habits (11%), rectal pain (4%), or were asymptomatic and discovered on screening proctosigmoidoscopy (22%). The tumors were located from the anal verge to 8 cm proximally and ranged in size from 1 to 4 cm. Pathologic findings included adenocarcinoma (92%), squamous cell carcinoma (4%), and cloacogenic carcinoma (4%). Postoperative hospitalization averaged two days (0 to 29 days). One patient died of a perioperative myocardial infarction for an operative mortality of 3 per cent. Morbidity was 7 per cent and included urinary retention and pneumonia. Postoperative radiation therapy was administered to 11 patients with either undifferentiated tumors or invasion into the muscularis propria. Follow-up in these 38 patients averaged 30 months. One patient died of metastatic carcinoma, and two patients developed local recurrence that was treated successfully by a low anterior resection or abdominoperineal resection. Transanal excision of rectal carcinoma can be performed in properly selected patients with good overall survival and local control.

Entities:  

Mesh:

Year:  1995        PMID: 7618812

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  2 in total

1.  Tolerability and safety of adjuvant chemoradiotherapy with S-1 after limited surgery for T1 or T2 lower rectal cancer.

Authors:  Mitsuyoshi Tei; Shingo Noura; Masayuki Ohue; Masatoshi Kitakaze; Hidekazu Takahashi; Norikatsu Miyoshi; Mamoru Uemura; Tsunekazu Mizushima; Kohei Murata; Yuichiro Doki; Hidetoshi Eguchi
Journal:  Int J Clin Oncol       Date:  2021-07-27       Impact factor: 3.402

2.  Postoperative Chemoradiotherapy After Local Resection for High-Risk T1 to T2 Low Rectal Cancer: Results of a Single-Arm, Multi-Institutional, Phase II Clinical Trial.

Authors:  Takeshi Sasaki; Yoshinori Ito; Masayuki Ohue; Yukihide Kanemitsu; Takaya Kobatake; Masaaki Ito; Yoshihiro Moriya; Norio Saito
Journal:  Dis Colon Rectum       Date:  2017-09       Impact factor: 4.585

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.